2Buja LM, Willerson JT. Clinicopathologic correlates of acute ischemic heart disease syndromes. Am J Cardiol,1981,47:343-356.
3Van der Wal AC, Becker AE, Van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.Circulation,1994,89:36-44.
4Jang YS, Lincoff AM, Plow EF, et al. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol,1994,24:1591-1601.
5Lehr H, Hubner C, Nolte D, et al. Oxidatively modified human low density lipoprotein stimulates leukocyte adherence to the microvascular endotheliumin vivo. Res Exp Med,1991,191:85-90.
6Kim RS, LaBella FS. Comparison of analytical methods for monitoring auto-oxidation profiles of authentic lipids. J Lipid Res,1987,28:1110-1117.
7Sinikka K, Enockson C, Lopes-virella MF, et al. Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low density lipoproteins. Clin And Diagno Lab Immuno,1998,5:817-822.
8Pigott R, Dillon LP, Hemingway IH, et al. Soluble form of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun,1992,187:584-589.
9Palinski W, Yla-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein.Arteriosclerosis,1990,10:325-333.
10Danial Steinberg. Lewis a conner memorial lecture-oxidative modification of LDL and atherogenesis. Circulation, 1997,95:1062-1071.
